Skip to content

Research at St Andrews

The use of cannabinoids in multiple sclerosis

Research output: Contribution to journalArticle

Author(s)

Lara Teare, John Zajicek

School/Research organisations

Abstract

Naturally occurring cannabinoids including Delta9-tetrahydrocannabinol and cannabidiol as well as endocannabinoids and synthetic cannabinoids may have a role in modulating experimental models of multiple sclerosis. Recent clinical studies to treat symptoms of multiple sclerosis have shown varying results, which may reflect issues relating to the way in which such studies were conducted. There is now increasing interest in the potential role of cannabinoids not only in symptom relief, but also for their possible neuroprotective actions.

Close

Details

Original languageEnglish
Pages (from-to)859-69
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume14
Issue number7
DOIs
Publication statusPublished - Jul 2005

    Research areas

  • Animals, Cannabinoid Receptor Modulators, Cannabinoids, Humans, Multiple Sclerosis, Neuroprotective Agents, Pain, Receptors, Cannabinoid

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study

    Carroll, C. B., Webb, D., Stevens, K. N., Vickery, J., Eyre, V., Ball, S., Wyse, R., Webber, M., Foggo, A., Zajicek, J., Whone, A. & Creanor, S., 7 Oct 2019, In : BMJ Open. 9, 10, 11 p., e029740.

    Research output: Contribution to journalArticle

  2. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis

    Freeman, J. A., Hendrie, W., Jarrett, L., Hawton, A., Barton, A., Dennett, R., Jones, B., Zajicek, J. P. & Creanor, S., 1 Aug 2019, In : Lancet Neurology. 18, 8, p. 736-747

    Research output: Contribution to journalArticle

  3. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT

    Gunn, H., Andrade, J., Paul, L., Miller, L., Creanor, S., Stevens, K., Green, C., Ewings, P., Barton, A., Berrow, M., Vickery, J., Marshall, B., Zajicek, J. P. & Freeman, J., 1 Jun 2019, In : Health Technology Assessment. 23, 27, p. 1-166

    Research output: Contribution to journalArticle

  4. Machine-learning based identification of undiagnosed dementia in primary care: a feasibility study

    Jammeh, E. A., Carroll, C. B., Pearson, S. W., Escudero, J., Anastasiou, A., Zhao, P., Chenore, T., Zajicek, J. & Ifeachor, E., 12 Jun 2018, In : BJGP Open. 2, 2, 13 p., bjgpopen18X101589.

    Research output: Contribution to journalArticle

  5. Improving the quality of cognitive screening assessments: ACEmobile, an iPad-based version of the Addenbrooke's Cognitive Examination-III

    Newman, C. G. J., Bevins, A. D., Zajicek, J. P., Hodges, J. R., Vuillermoz, E., Dickenson, J. M., Kelly, D. S., Brown, S. & Noad, R. F., 2018, In : Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 10, p. 182-187 6 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents

    Cevik, M. & Orkin, C., 18 Nov 2019, In : Expert Opinion on Investigational Drugs. Latest Articles, p. 1-4

    Research output: Contribution to journalEditorial

ID: 242972517

Top